Rodolfo Elias Alcedo-Guardia

Dr. Rodolfo Elias Alcedo-Guardia

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AKAri D. Kappel
Ari D. Kappel
RJRohan Jha
Rohan Jha
SGSaibaba Guggilapu
Saibaba Guggilapu
WSWilliam J. Smith
William J. Smith
AFAbdullah H. Feroze
Abdullah H. Feroze
JBJoshua Bernstock
Joshua Bernstock
High-grade gliomas (HGGs) have a poor prognosis and are difficult to treat. This review examines the evolving landscape of endovascular therapies for HGGs. Recent advances in endovascular catheter technology and delivery methods allow for super-selective intra-arterial cerebral infusion (SSIACI) with increasing precision. This treatment modality may offer the ability to deliver anti-tumoral therapies directly to tumor regions while minimizing systemic toxicity. However, challenges persist, including blood–brain barrier (BBB) penetration, hemodynamic complexities, and drug–tumor residence time. Innovative adjunct techniques, such as focused ultrasound (FUS) and hyperosmotic disruption, may facilitate BBB disruption and enhance drug penetration. However, hemodynamic factors that limit drug residence time remain a limitation. Expanding therapeutic options beyond chemotherapy, including radiotherapy and immunobiologics, may motivate future investigations. While preclinical and clinical studies demonstrate moderate efficacy, larger randomized trials are needed to validate the clinical benefits. Additionally, future directions may involve endovascular sampling for peri-tumoral surveillance; changes in drug formulations to prolong residence time; and the exploration of non-pharmaceutical therapies, like radioembolization and photodynamic therapy. Endovascular strategies hold immense potential in reshaping HGG treatment paradigms, offering targeted and minimally invasive approaches. However, overcoming technical challenges and validating clinical efficacy remain paramount for translating these advancements into clinical care.

6 October 2025 in Journal of Neurosurgery: Case Lessons
Verified
Journal Article
Open access
EREsteban Ruben Rivera-Rivera
Esteban Ruben Rivera-Rivera
AAAlexander I. Acevedo-Jetter
Alexander I. Acevedo-Jetter
ACAlejandro E. Cedeño-Morán
Alejandro E. Cedeño-Morán
GTGrecia Negron Torres
Grecia Negron Torres
RARodolfo Elias Alcedo-Guardia
Rodolfo Elias Alcedo-Guardia
BACKGROUND: Stroke is the leading cause of disability and the fifth leading cause of death nationwide, with large-vessel occlusions (LVOs) contributing significantly to this burden. The risk of LVO increases in hypercoagulable states such as pregnancy; however, LVOs in pregnancy are rare. Management of this condition lacks well-established guidelines due to the exclusion of pregnant women from clinical trials. Case reports of alteplase and mechanical thrombectomy (MT) use during pregnancy suggest therapeutic potential; however, there is less evidence for agents such as tenecteplase (TNK). OBSERVATIONS: The authors present the case of a 27-year-old woman, G5P2A2, at 4 weeks’ gestation who presented with seizure-like activity, expressive aphasia, and right-sided hemiparesis, NIH Stroke Scale score of 21. The patient was diagnosed with an ischemic stroke. TNK was administered without symptom resolution, and the patient was transferred to the authors’ center. Imaging demonstrated left M2 occlusion, and MT was performed successfully. The patient carried the pregnancy to term and delivered a healthy infant at 37 weeks. LESSONS: To the authors’ knowledge, this represents the first formally reported case of LVO treated with TNK and MT in the first trimester of pregnancy. More data are needed to determine whether these interventions are safe for patients with LVOs during the first trimester of pregnancy. https://thejns.org/doi/10.3171/CASE25126

1 May 2026 in Stroke: Vascular and Interventional Neurology
Verified
Journal Article
Open access
AGArnab Ghosh
Arnab Ghosh
NNNoah Nawabi
Noah Nawabi
DADiana Alcedo
Diana Alcedo
RARodolfo Elias Alcedo-Guardia
Rodolfo Elias Alcedo-Guardia
JVJuan Vicenty-Padilla
Juan Vicenty-Padilla
JBJoshua Bernstock
Joshua Bernstock
BACKGROUND: Timely identification of stroke subtype is critical for triage and treatment. Existing prehospital stroke scales have limited diagnostic accuracy, especially in differentiating large vessel occlusion (LVO) from intracerebral hemorrhage (ICH). The LVOne point-of-care test measures d -dimer and GFAP (glial fibrillary acidic protein), biomarkers associated with thrombotic and hemorrhagic stroke, enabling biologically informed triage. METHODS: We validated a new version of the LVOne assay using plasma samples from 210 suspected stroke patients presenting within 6 hours of symptom onset, enrolled in the TIME (Testing of Identification Markers for Stroke) prospective observational cohort. This article reports a retrospective (secondary) laboratory analysis of these prospectively collected samples and clinical data. Samples were collected before neuroimaging or thrombolysis. LVOne version 1 combined d -dimer positivity, GFAP negativity, and Field Assessment Stroke Triage for Emergency Destination scoring for LVO detection only; version 2 uses improved GFAP measurement and a clinical decision rule enabling simultaneous diagnosis of LVO and ICH. Diagnostic performance (sensitivity, specificity, positive predictive value, negative predictive value) was calculated for each version. Receiver operating characteristic analyses and biomarker correlations with Field Assessment Stroke Triage for Emergency Destination were also performed. RESULTS: Both LVOne versions achieved high accuracy for LVO detection (sensitivity, 0.75; specificity, 0.92; negative predictive value, 0.97). Version 2 improved ICH specificity (0.99 versus 0.90) and positive predictive value (0.83 versus 0.23) versus version 1. Biomarker levels correlated with Field Assessment Stroke Triage for Emergency Destination scores but with limited explanatory power (GFAP R 2 =0.077; d -dimer R 2 =0.047), suggesting added information beyond clinical severity scales. In a specimen-matrix comparison (n=25), qualitative GFAP/ d -dimer classification was concordant across plasma, venous whole blood, and capillary whole blood. CONCLUSIONS: The updated LVOne assay enables simultaneous biomarker-based identification of both LVO and ICH in suspected stroke patients. Its rapid, low-complexity format supports prehospital use and may improve triage, reduce time to treatment, and optimize outcomes. Prospective field validation is warranted. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04292600.